CSIMarket
 
Twist Bioscience Corporation  (NASDAQ: TWST)
 
Price: $139.0000 $-2.38 -1.683%
Day's High: $140.5800018310547 Week Perf: -8.2 %
Day's Low: $ 135.00 30 Day Perf: 51.83 %
Volume (M): 1,889,936 52 Wk High: $ 155.44
Volume (M$): $ 0 52 Wk Avg: $55.98
Open: $139.34 52 Wk Low: $23.30



 Market Capitalization (Millions $) 8,577
 Shares Outstanding (Millions) 62
 Employees 979
 Revenues (TTM) (Millions $) 409
 Net Income (TTM) (Millions $) -81
 Cash Flow (TTM) (Millions $) -88
 Capital Exp. (TTM) (Millions $) 45

Business Description


Twist Bioscience Corporation is a synthetic biology company that specializes in producing high-quality DNA strands for a wide range of applications. Headquartered in San Francisco, California, Twist Bioscience was founded in 2013 and has grown to become a leading player in the field of synthetic biology.

One of the primary focuses of Twist Bioscience is the production of synthetic DNA strands, which it sells to customers in the pharmaceutical, academic, and industrial sectors. The company uses a proprietary process to manufacture DNA strands, which allows it to produce large quantities of high-quality, double-stranded DNA quickly and inexpensively.

In addition to its core synthetic DNA business, Twist Bioscience also offers a range of other products and services. These include custom gene synthesis, which allows customers to design and order specific DNA sequences for use in research and development; NGS (Next-Generation Sequencing), which allows researchers to analyze large quantities of genomic data quickly and accurately; and CRISPR gene editing, which employs a revolutionary method for altering DNA sequences with precision.

Twist Bioscience's technology platform is based on a proprietary silicon-based microchip that is capable of synthesizing millions of different DNA strands simultaneously. The company's expertise in DNA synthesis and gene editing has opened up a wide range of potential applications, including drug discovery, genetic engineering, and precision medicine.

Twist Bioscience is well-positioned in the emerging field of synthetic biology, a rapidly growing area of biotechnology that seeks to engineer biological systems for specific applications. The company is backed by a strong team of scientific experts and experienced business leaders, and has raised significant funding from top-tier investors, including ARCH Venture Partners, Illumina, and Fidelity Investments.

In summary, Twist Bioscience is a cutting-edge synthetic biology company that specializes in DNA synthesis and gene editing. Its proprietary technology platform and expertise in the field of synthetic biology have opened up a range of exciting potential applications, and the company is well-positioned to continue to lead in this exciting and rapidly growing field.


   Company Address: 681 Gateway Blvd South San Francisco 94080 CA
   Company Phone Number: 719-0671   Stock Exchange / Ticker: NASDAQ TWST


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRSP   -0.17%    
GLUE        1.2% 
RGEN   -0.35%    
TECH   -0.11%    
A        0.08% 
BIO        1.14% 
• View Complete Report
   



Business Update

Accelerating Next-Generation Sequencing The Collaborative Breakthrough of Twist Bioscience and Element Biosciences

Published Thu, May 22 2025 3:17 PM UTC

In an era characterized by rapid advancements in genomic technologies, the collaboration between Twist Bioscience Corporation and Element Biosciences signifies a pivotal step toward optimizing next-generation sequencing (NGS) workflows. This article interprets the implications of their expanded partnership as detailed in recent announcements, assessing the potential impact...

Business Update

Pioneering Biotech Advances Twist Bioscience Showcases Growth and Innovation at the J.P. Morgan Healthcare Conference

Published Thu, Dec 19 2024 1:47 PM UTC

Twist Bioscience: Leading the Charge in Biotechnological Innovation at the Upcoming J.P. Morgan Healthcare Conference South San Francisco, CA As the landscape of the life sciences sector continues to evolve, Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in synthetic DNA technology, is set to further solidify its position at the 43rd Annual J.P. Morgan Hea...

Business Update

Twist Bioscience Pioneering Green Innovation in Biotechnology for a Sustainable Tomorrow,

Published Mon, Sep 9 2024 12:47 PM UTC

Embracing Sustainability in Biotechnology: Twist Bioscience s Commitment to Corporate ResponsibilityIn a landscape increasingly dominated by environmental concerns and the quest for sustainability, Twist Bioscience Corporation (NASDAQ: TWST) has made significant strides with the release of its 2024 Corporate Responsibility Report. This document sheds light on the company s ...

Business Update

Twist Bioscience Enhances High-Throughput Antibody Portfolio with CHO Express Antibodies

Published Wed, Jul 10 2024 3:47 PM UTC

Twist Bioscience Corporation, a leading provider of high-quality synthetic DNA using its innovative silicon platform, has recently expanded its high-throughput antibody portfolio. The company announced the launch of a CHO (Chinese hamster ovary) cell line for its Twist Express Antibodies, complementing its existing HEK293 expression system. This development aims to address t...

Business Update

Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A

Published Tue, Jul 9 2024 12:47 PM UTC

Advances in Synthetic Biology: Twist Bioscience s New Launches in Viral Controls and High-Throughput ScreeningTwist Bioscience Corporation (NASDAQ: TWST), a company renowned for its innovations in synthetic DNA using its proprietary silicon platform, has recently announced two significant advancements designed to meet the growing demands in viral research and high-throughpu...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 20.95
Price to Sales (Expected) -
Price to Book 18.85
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.43
Working Capital Ratio 2.7
Leverage Ratio (MRQ) 0.49
Total Debt to Equity 0.03
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.33 $
Revenues (TTM) 6.64 $
Cash Flow (TTM) -
Cash 2.78 $
Book Value 7.38 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 418,263
Net Income per Employee (TTM) -83,019
Receivable Turnover Ratio (TTM) 7.41
Inventory Turnover Ratio (TTM) 6.5
Asset Turnover Ratio (TTM) 0.63

Profitability Ratios Current
Gross Margin (MRQ) 51.59 %
Operating Margin (MRQ) -41.42 %
Net Margin (MRQ) -39.76 %
Net Cash Flow Margin (MRQ) -23.6 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Twist Bioscience's Segments
Americas    58.08 % of total Revenue
EMEA    33.73 % of total Revenue
APAC    8.18 % of total Revenue
DNA synthesis and protein solutions    48.12 % of total Revenue
NGS applications    51.88 % of total Revenue
Therapeutics    36.82 % of total Revenue
Diagnostics    36.09 % of total Revenue
Industry and applied    5.24 % of total Revenue
Academic research and government    11.58 % of total Revenue
Global supply partners    10.28 % of total Revenue
Reportable Segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.